Klinefelter syndrome is a frequent cause of hypogonadism, but despite hundreds of publications on different aspects of Klinefelter syndrome, only a few studies dealt with sexual dysfunction. In particular, testosterone is critical for various aspects of sexual response, but its role on sexuality in Klinefelter syndrome patients is debatable and no studies have evaluated the efficacy of testosterone treatment on sexual dysfunction in these subjects. Furthermore, the impact of psychological and relational aspects on sexual function of Klinefelter syndrome subjects is poorly defined. In this study, we aimed to determine the presence and type of sexual dysfunctions in Klinefelter syndrome subjects; to correlate them with testosterone levels and psychosexological and relational domains; and to evaluate the effects of testosterone therapy. We studied 62 non-mosaic na€ ıve Klinefelter syndrome patients and 60 agematched controls by means of medical history, psychosexological history, 15-item International Index of Erectile Function questionnaire, endocrine assessment, and dynamic penile color Doppler ultrasound. Twenty-five hypogonadal Klinefelter syndrome patients were studied after 6 months of testosterone replacement therapy. Klinefelter syndrome subjects have reduced 15-item International Index of Erectile Function scores regarding sexual desire, intercourse satisfaction, and overall satisfaction with respect to controls, and these aspects were significantly associated with testosterone levels. Klinefelter syndrome subjects had also higher prevalence of erectile dysfunction, but no relation with testosterone levels was evident. A high prevalence of a range of psychological disturbances was present in Klinefelter syndrome subjects with erectile dysfunction with respect to those without erectile dysfunction. No statistical difference in the prevalence of premature and delayed ejaculation was observed between Klinefelter syndrome and control subjects. Testosterone replacement therapy improved sexual desire, intercourse satisfaction, and overall satisfaction scores, but had no effect on erectile function. Penile color Doppler ultrasound was normal in all subjects. This study shows that sexual dysfunction in Klinefelter syndrome is multifactorial and related only in part to hypogonadism and largely to psychological disturbances. Evaluation and therapy of sexual dysfunction should include a combined andrological and psychosexological approach.
INTRODUCTION
Klinefelter syndrome (KS) is the most common sex chromosomal disorder, with a prevalence of 1 : 600, and it is a frequent form of male hypogonadism and infertility (Lanfranco et al., 2004; Bonomi et al., 2017) . The clinical features of KS commonly include hypergonadotropic hypogonadism, small testes, and infertility (Klinefelter et al., 1942) , but KS may be associated also with an increased risk of systemic diseases including malignancies, venous thromboembolism, diabetes, cardiovascular and metabolic diseases, and osteoporosis Bojesen & Gravholt, 2011; Nieschlag et al., 2016; Bonomi et al., 2017; Calogero et al., 2017) . Neuropsychological and cognitive aspects are also quite typical in KS and have been investigated in numerous studies, which showed that a large proportion of KS patients suffer from some degree of verbal disabilities (Bender et al., 1986; Rovet et al., 1996; Fales et al., 2003; Steinman et al., 2009; Skakkebaek et al., 2015) and might also display impairments in executive function related to attention, response inhibition, flexibility and planning (Ross et al., 2008; Bruining et al., 2009; Kompus et al., 2011; Skakkebaek et al., 2014 Skakkebaek et al., , 2016 , and a characteristic personality profile, characterized by a higher level of neuroticism and lower levels of extraversion, openness, and conscientiousness (Paduch et al., 2008) . Furthermore, KS seems to be associated with an increased level of psychological distress, which may predispose these patients to psychiatric disorders such as depression and anxiety (Ross et al., 2008) .
One of the less studied areas in KS research is related to sexual function. Very few studies dealt with sexual aspects, and the role of hypogonadism and neurocognitive, psychological, and relational disturbances has not been elucidated. Early studies reported that KS subjects have a weakened sexual power (Raȋ-kaia, 1972) , tend to marry older women, frequently divorce because of sexual life (Money et al., 1974) , are sexually less active (Nielsen et al., 1982) , and recur less to masturbation during adolescence and sexual intercourses in marriage (Yoshida et al., 1997) . Yoshida found that 67.5% of KS subjects showed a disturbance in their sexual function, a prevalence however not different from a control group (Yoshida et al., 1997) . More recent studies showed that KS is associated with hypersexuality, paraphilic behaviors, and gender dysphoria, mediated by obsessive-compulsive and autistic traits (Fisher et al., 2015) , and with significant lower libido and incidence of premature ejaculation with respect to controls (El Bardisi et al., 2017) . The role of T levels and hypogonadism in sexual dysfunction of KS subjects has been poorly defined. Indeed, it has been well-known that testosterone (T) plays a physiological role in various aspects of sexual response, starting from sexual desire, arousal, orgasm, and ejaculation. Corona reported in KS patients the presence of severe erectile dysfunction (ED), hypoactive sexual desire (HSD), and premature and delayed ejaculation . However, these associations disappeared when patients with KS were compared with age, smoking habit, and T matched controls, allowing the authors to conclude that sexual dysfunction in KS is mainly related to the underlying hypogonadal state.
However, the role of T on sexuality in KS patients is still debatable and robust studies evaluating the efficacy of T treatment on sexual dysfunction in these subjects have not been performed. Only one study on four adult men with KS, low normal testosterone levels, and normal sexual activity and interest treated with oral T undecanoate has been published and showed a modest increase in sexual interest after treatment (Wu et al., 1982) . Furthermore, the impact of psychological and relational aspects on sexual function of KS subjects is poorly defined. In this study, we aimed to determine the presence and type of sexual dysfunctions in KS subjects; to correlate them with T levels and psychological, sexological, and relational domains; and to evaluate the effects of T therapy.
SUBJECTS AND METHODS

Patients and clinical analysis
We prospectively studied 62 non-mosaic na€ ıve KS patients (mean age 31.2 AE 8.0 years; range 18-58 years), diagnosed at the Unit of Andrology and Reproductive Medicine of the University-Hospital of Padova from January 2012 to July 2015 after referral for fertility problems or testicular hypotrophy. As controls, 60 age-matched healthy (good general condition) men (mean age 30.9 AE 8.4 years; range 19-45 years) were recruited through an andrological screening program (Ferlin et al., 2015) . All KS subjects had non-mosaic 47,XXY karyotype after evaluation of at least 50 peripheral blood lymphocyte metaphases and had never received T substitution at the time of evaluation. Patients with more than one supernumerary X chromosome, mosaicisms, or with any endocrine dysfunction different from hypogonadism and subjects assuming any drug were excluded from the study. The study has been approved by the Hospital Ethics Committee, and each participant gave his written informed consent.
Subject evaluation included complete medical history (pubertal history, lifestyle, physical activity, smoking, alcohol misuse), physical examination (weight, height, body mass index [BMI] , waist circumference, arm span), lipid and glucose metabolism (total cholesterol, HDL, triglycerides, fasting glucose), complete blood count, serum insulin, and PSA. Homeostasis model assessment for insulin resistance (HOMA-IR) was calculated as fasting insulin (lIU/mL) 9 fasting glucose (mmol/L)/22.5. Serum levels of total T, estradiol, LH, FSH, prolactin, and TSH (thyroid-stimulating hormone) were measured in all subjects as previously reported (De Toni et al., 2016) . Hypogonadism was defined as total testosterone <10.4 nmol/L (Bhasin et al., 2010) .
All patients were interviewed by andrologists and psychosexologists prior to the beginning of any treatment, and before any specific diagnostic procedures about medical history, sexological/affective history, and information about the partner, and were specifically interviewed to investigate the possible presence of difficulties in cognitive, relational, and sexual problems during their life, specifically whether they had encountered problems of attention, memory or language, anxiety, depression, low self-esteem, and sexual and relational insecurity. Subjects completed the 15-item International Index of Erectile Function (IIEF-15) questionnaire for the evaluation of ED, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction (Cappelleri et al., 1999) . Furthermore, self-reported IELT (intravaginal ejaculatory latency time) and PEDT (Premature Ejaculation Diagnostic Tool) questionnaire (Symonds et al., 2007) was compiled. IELT ≤1 min that occurred in >90% of sexual intercourse episodes, associated with the inability to delay ejaculation and positive score to PEDT were defined as PE (premature ejaculation) patients. Delayed ejaculation (DE) was defined as personal distress caused by the persistent or recurrent delay, difficulty, or absence of orgasm after sufficient sexual stimulation (Lue et al., 2004) .
Penile color Doppler ultrasonography (P-CDU) was performed in KS subjects affected by ED at a high resolution (iU22; Philips, Best, the Netherlands) after intracavernosal injection of 10 lg alprostadil (Caretta et al., 2005) . Cavernosal peak systolic velocity (PSV) and intima-media thickness (IMT) were measured (Caretta et al., 2006) .
Of 62 patients, 33 had hypogonadism and were treated with Tgel 2% (Tostrex; ProStrakan, Galashiels, UK), dose adapted to maintain plasma T levels between 12 and 18 nmol/L. Twentyfive patients completed the 6-month treatment protocol and were re-evaluated at the end of therapy by means of total T, estradiol, LH, FSH, complete blood count, PSA, and IIEF questionnaire.
Statistical analysis
Data in the tables are reported as mean AE SD of the mean. Differences between KS patients and controls and in KS before and after treatment were evaluated by unpaired two-sided Student's t-test (for normally distributed data) and Mann-Whitney U-test (for non-normally distributed data). Comparisons between the percentages were performed with chi-square test.
Relationships between continuous variables were assessed using Pearson's r (for normally distributed data) and Spearman's q (for non-normally distributed data) correlation tests. The significance level was set to p < 0.05. Table 1 reports that KS patients had, as expected, significantly higher weight, waist circumference, BMI, and gonadotropin levels, and significantly reduced levels of total T with respect to controls. Glycaemia, insulin, HOMA-IR, and total cholesterol were significantly higher, whereas HDL-cholesterol significantly reduced in KS patients with respect to controls. Age, height, arm span, PSA, and triglycerides did not show significant differences between patients and controls.
RESULTS
Ninety-two percent (57/62) of patients currently masturbate and/or masturbated in the past, starting at a median age of 15 years. The median age of the first sexual intercourse was 19.5 years. Sixty-eight percent (42/62) of patients had a steady relationship with a partner, and almost half of the relations were characterized by conflicts between partners (47.6%, 20/42). One patient (1/62, 1.6%) referred homosexuality.
Almost half of KS subjects (29/62, 46.7%) reported one or more psychological problems, in cognitive, relational, and/or sexual domain. In particular, 15/29 (51.8%) reported relational and sexual problems during puberty and early adulthood, a difficulty that has affected the possibility of building emotional and sexual relationships with the opposite sex; 3/29 subjects (10.3%) reported negative feelings about their body, including the idea of the small penis, disappointment caused by the small size of the testicles, or a poor body image; 7/29 (24.2%) reported cognitive difficulties related to memory, language, or the ability to focus and concentration; 3/29 (10.3%) reported anxiety disorders or depressive episodes; and one patient (3.4%) was under psychiatric treatment for several years. Figure 1 shows the results of IIEF-15 questionnaire. KS subjects had, with respect to controls, scores significantly reduced in the sexual desire (7.3 AE 1.8 vs. 9.0 AE 1.2; p < 0.0001), intercourse satisfaction (10.6 AE 4.2 vs. 13.4 AE 2.1; p < 0.0001), overall satisfaction (7.7 AE 2.7 vs. 9.1 AE 1.1; p < 0.0005), and erectile function (26.3 AE 6.6 vs. 28.2 AE 2.1; p < 0.05) domains.
No differences were found between KS subjects and controls in the incidence of PE (11.3% vs. 8.3%) and DE (6.4% vs. 5.0%).
Sexual desire, intercourse satisfaction, and overall satisfaction were positively associated with T levels in the KS group (respectively, R = 0.36; p < 0.005; R = 0.25; p < 0.05; R = 0.31; p < 0.05) (Fig. 2) . On the contrary, no correlation was found between erectile function, orgasmic function, and T levels.
Among KS subjects, 14 (22.6%) had ED: 7/62 had mild dysfunction, 3/62 moderate dysfunction, and 4/62 severe dysfunction. This figure was statistically higher with respect to controls (3/60, 5%; p < 0.005). P-CDU performed in these 14 ED patients showed no vascular alteration (data not shown).
The percentage of psychological disturbances (outlined above) in KS patients affected by ED was 85.7% (12/14), significantly higher with respect to the percentage of psychological disturbances in KS patients without ED (35.4%, 17/48; p < 0.001).
Twenty-five hypogonadal KS subjects were re-evaluated after a 6-month period of T replacement therapy (Table 2) . IIEF-15 questionnaire after T therapy showed significantly increased scores in sexual desire, intercourse satisfaction, and overall satisfaction domains. Erectile function and orgasmic function were not significantly different before and after T therapy.
DISCUSSION
This study shows that KS subjects have lower sexual desire, intercourse satisfaction, and overall satisfaction with respect to controls and these domains were significantly associated with T levels and were significantly improved after T therapy. KS subjects had also reduced erectile function score and higher prevalence of ED, but not relation to T levels and T therapy was evident. In general, KS subjects have a wide range of neurocognitive, psychosexological, and relational problems, and ED symptom is particularly associated with these disturbances. No difference in the prevalence of PE and DE was observed between KS and control subjects. As P-CDU was normal in subjects with ED, excluding therefore a vasculogenic origin of the dysfunction, this study shows that ED in KS is mainly linked to psychological disturbances, whereas other domains (sexual desire, intercourse satisfaction, and overall satisfaction) are related also to T levels and the hypogonadal state. One strength of our study is that we did not limit the evaluation of sexual function to questionnaires, but indeed performed psychosexological interview that allowed us to have much more information on many aspects of the psychological, relational, and sexual history and function of patients, not evident from just questionnaires. On the other hand, a limitation of our study is the absence of a control group for psychological and relational aspects. However, some findings, such as the high prevalence of negative feeling about their body, the idea of small penis, cognitive difficulties related to memory and language or the ability to focus and concentration, sexual problems during puberty and early adulthood, and the frequent inability to building emotional and sexual relations with the opposite sex, seem to be over-represented in KS.
Our results are in part in agreement with the few published studies on this topic and expand our knowledge in this field. The strength of our study is related to the combined, medical (including biochemical, hormonal, and P-CDU) and psychosexological, approach and to the evaluation of sexual function at baseline and after T replacement therapy. The percentage of ED among our KS cohort (14/62, 22.6%) is absolutely comparable to that found by Corona (5/23, 21 .7%) and El Bardisi (10/53, 18.9%) (El Bardisi et al., 2017) . The prevalence of PE and DE was also similar between our study and that of Corona, but lower than that found by El Bardisi (22.6% of PE). Corona found higher prevalence of HSD (60.9%), a figure similar to that reported by El Bardisi as low libido (54.7%). However, although methods for determining HSD or low libido are different among these studies, we also found lower scores in sexual desire, intercourse satisfaction, and overall satisfaction in KS subjects, suggesting that these sexual symptoms are a common feature of KS.
A recent study (Skakkebaek et al., 2017) dealing with determinants of quality of life in KS subjects also evaluated sexual function by a survey including IIEF-15 and found that while overall sexual dysfunction was only marginally associated with KS status, men with KS reported significantly more erectile dysfunction, decreased orgasmic function, and lower intercourse satisfaction, as well as delayed ejaculation. This study also reported that KS subjects are less self-confident as a man and sex partner and have lower quality of life that is, directly and indirectly, related to sexual function itself. The data, although interesting, are not directly comparable to our study, because study population was different (na€ ıve patients in our study, 95/ 124 (76.6%) 47,XXY subjects currently receiving T treatment in the study of Skakkebaek), no biochemical and hormonal data were determined, P-CDU was not assessed, comparison before and after T treatment was not made, and in general, data were collected through survey rather than combined medical and psychosexological outpatient approach. Indeed, our study was designed to elucidate the intricate pathogenesis of sexual dysfunction in KS between hypogonadism, psychosexological factors, and vascular problems, and to study the effect of T replacement therapy. Already Corona suggested that HSD is more probably related to the underlying hypogonadism, but had no direct data on this relationship. Actually, we showed that low T represents a R = 0.36; p < 0.005 R = 0.25; p < 0.05 R = 0.31; p < 0.05 Figure 2 Relations between T levels and 15-Item International Index of Erectile Function scores for sexual desire, intercourse satisfaction, and overall satisfaction in Klinefelter syndrome subjects. major cause of low libido and sexual satisfaction and these domains are positively improved by restoring normal T concentrations. This result confirms that also in KS, low testosterone represents one of the major causes of low libido, and is in agreement with the positive effects of T treatment in other hypogonadal populations (Isidori et al., 2005) . On the contrary, erectile function seems less dependent on T levels and hypogonadism and T replacement therapy is not able to improve it. Two aspects merit further attention in this context. First, 6 months of therapy might not be a sufficient lapse of time to having significant effect on erectile function. Secondly, and in our view more importantly, ED in KS subjects is very frequently associated (and probably caused) with a variety of psychosexological and relational problems, which obviously are not influenced by T treatment.
In conclusion, our findings reinforce the hypothesis that in KS, T levels, hypogonadal status, and libido are strongly related and that correction of low T is associated with an improvement of this symptom. On the contrary, ED has a different pathogenesis in most cases, poorly related to T deficiency and T replacement. Psychological symptoms seem to represent a determining factor in erectile function and dysfunction in these subjects, highlighting that the clinical approach should be multidisciplinary with andrologists and psychosexologists working together for a correct diagnosis and more successful treatment.
